Lv2
140 积分 2023-07-20 加入
Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial
1天前
待确认
Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial
1天前
已完结
Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors
23天前
已完结
Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors
1个月前
已完结
Emerging Therapeutic Approaches for Anemia in Myelofibrosis
1个月前
已完结
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience
1个月前
已完结
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
1个月前
已关闭
Cytokine storm
1个月前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
1个月前
已完结
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
2个月前
已完结
皖公网安备34019202002308
